State Street’s TG Therapeutics TGTX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$287M Buy
8,649,766
+169,767
+2% +$5.06M 0.01% 773
2025
Q4
$253M Buy
8,479,999
+379,380
+5% +$12.4M 0.01% 820
2025
Q3
$293M Buy
8,100,619
+482,381
+6% +$15.9M 0.01% 750
2025
Q2
$274M Buy
7,618,238
+184,339
+2% +$6.86M 0.01% 745
2025
Q1
$293M Sell
7,433,899
-1,766,009
-19% -$59.4M 0.01% 697
2024
Q4
$277M Buy
9,199,908
+105,750
+1% +$3.03M 0.01% 750
2024
Q3
$213M Buy
9,094,158
+2,398,015
+36% +$52.4M 0.01% 888
2024
Q2
$119M Sell
6,696,143
-1,100,436
-14% -$17.6M 0.01% 1160
2024
Q1
$119M Sell
7,796,579
-456,994
-6% -$7.28M 0.01% 1199
2023
Q4
$141M Sell
8,253,573
-1,564,049
-16% -$18.2M 0.01% 1066
2023
Q3
$82.1M Buy
9,817,622
+4,189,436
+74% +$58.4M ﹤0.01% 1312
2023
Q2
$140M Sell
5,628,186
-2,015,619
-26% -$52.1M 0.01% 1008
2023
Q1
$115M Sell
7,643,805
-2,771,356
-27% -$42.1M 0.01% 1089
2022
Q4
$123M Sell
10,415,161
-1,335,239
-11% -$9.69M 0.01% 1043
2022
Q3
$69.6M Sell
11,750,400
-2,484,863
-17% -$16.3M ﹤0.01% 1362
2022
Q2
$60.5M Buy
14,235,263
+4,606,679
+48% +$28.8M ﹤0.01% 1502
2022
Q1
$91.6M Buy
9,628,584
+3,804,406
+65% +$44M ﹤0.01% 1352
2021
Q4
$111M Buy
5,824,178
+1,527,426
+36% +$39.7M 0.01% 1226
2021
Q3
$143M Buy
4,296,752
+684,605
+19% +$21.2M 0.01% 1022
2021
Q2
$140M Buy
3,612,147
+352,866
+11% +$13.9M 0.01% 1055
2021
Q1
$157M Sell
3,259,281
-453,561
-12% -$21.8M 0.01% 912
2020
Q4
$193M Sell
3,712,842
-396,277
-10% -$13.4M 0.01% 761
2020
Q3
$110M Sell
4,109,119
-918,008
-18% -$21.1M 0.01% 914
2020
Q2
$97.9M Buy
5,027,127
+1,532,474
+44% +$24.7M 0.01% 977
2020
Q1
$34.4M Buy
3,494,653
+89,348
+3% +$1.13M ﹤0.01% 1499
2019
Q4
$37.8M Sell
3,405,305
-505,419
-13% -$3.84M ﹤0.01% 1710
2019
Q3
$22M Sell
3,910,724
-1,319,257
-25% -$9.2M ﹤0.01% 2005
2019
Q2
$45.2M Buy
5,229,981
+1,953,015
+60% +$14.8M ﹤0.01% 1546
2019
Q1
$26.3M Sell
3,276,966
-1,065,652
-25% -$5.76M ﹤0.01% 1872
2018
Q4
$17.8M Buy
4,342,618
+206,901
+5% +$1.03M ﹤0.01% 2071
2018
Q3
$23.2M Buy
4,135,717
+423,614
+11% +$4.84M ﹤0.01% 2079
2018
Q2
$48.8M Buy
3,712,103
+593,842
+19% +$8.17M ﹤0.01% 1507
2018
Q1
$44.3M Sell
3,118,261
-293,405
-9% -$3.75M ﹤0.01% 1497
2017
Q4
$28M Buy
3,411,666
+159,201
+5% +$1.39M ﹤0.01% 1828
2017
Q3
$38.5M Buy
3,252,465
+613,782
+23% +$6.99M ﹤0.01% 1551
2017
Q2
$26.5M Buy
2,638,683
+1,933,896
+274% +$21.6M ﹤0.01% 1796
2017
Q1
$8.21M Buy
704,787
+25,672
+4% +$184K ﹤0.01% 2462
2016
Q4
$3.16M Buy
679,115
+42,760
+7% +$251K ﹤0.01% 2912
2016
Q3
$4.92M Buy
636,355
+12,048
+2% +$77.5K ﹤0.01% 2573
2016
Q2
$3.78M Sell
624,307
-556,731
-47% -$4.53M ﹤0.01% 2763
2016
Q1
$10.1M Buy
1,181,038
+39,117
+3% +$342K ﹤0.01% 2169
2015
Q4
$13.6M Sell
1,141,921
-1,493,102
-57% -$18.9M ﹤0.01% 1999
2015
Q3
$26.6M Buy
2,635,023
+542,774
+26% +$8.09M ﹤0.01% 1558
2015
Q2
$34.7M Buy
2,092,249
+424,565
+25% +$6.72M ﹤0.01% 1483
2015
Q1
$25.8M Buy
1,667,684
+1,311,768
+369% +$19.9M ﹤0.01% 1668
2014
Q4
$5.64M Buy
355,916
+84,524
+31% +$1.1M ﹤0.01% 2504
2014
Q3
$2.9M Buy
271,392
+48,749
+22% +$452K ﹤0.01% 2824
2014
Q2
$2.09M Buy
222,643
+13,656
+7% +$87.3K ﹤0.01% 3051
2014
Q1
$1.44M Buy
208,987
+66,433
+47% +$393K ﹤0.01% 3177
2013
Q4
$558K Sell
142,554
-13,210
-8% -$53.4K ﹤0.01% 3347
2013
Q3
$793K Buy
155,764
+97,833
+169% +$598K ﹤0.01% 3285
2013
Q2
$371K Buy
+57,931
New +$371K ﹤0.01% 3274

Other funds holding TGTX

State Street's TGTX Position: Q1 2026 in Review

State Street increased its TG Therapeutics (TGTX) stake by 2% in Q1 2026, buying an estimated $5.06M and bringing the position to 8,649,766 shares worth $287M. The position accounts for 0.01% of the portfolio, ranked #773.

State Street first reported a position in TGTX in Q2 2013 and has held it in 52 quarters since. The position peaked at $293M in Q1 2025. 363 funds tracked by Wall St. Rank hold TGTX as of Q1 2026.

  • State Street held 8,649,766 shares of TG Therapeutics worth $287M as of Q1 2026.
  • State Street bought 169,767 TG Therapeutics shares in Q1 2026, an estimated $5.06M.
  • TG Therapeutics made up 0.01% of State Street's portfolio in Q1 2026, its #773 holding.
  • State Street first reported a position in TG Therapeutics in Q2 2013 and has held it in 52 quarters since.
  • State Street's TG Therapeutics position peaked at $293M in Q1 2025.
  • 363 funds tracked by Wall St. Rank held TG Therapeutics as of Q1 2026.

Based on State Street's 13F filing for Q1 2026, filed 15 May 2026.